Abstract
Overexpression of transforming growth factor-beta isoforms (TGF-beta1, -beta2, -beta3) has been previously reported in human melanoma cell lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-beta isoforms in melanoma patients. Significantly elevated levels of TGF-beta1 (4.2 x the controls, P = 0.0094) and of TGF-beta2 (1.5 x the controls, P = 0.012) but not of TGF-beta3 were measured in patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive peptides of the TGF-beta family in end-stage melanoma patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krasagakis, K., Thölke, D., Farthmann, B. et al. Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma. Br J Cancer 77, 1492–1494 (1998). https://doi.org/10.1038/bjc.1998.245
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.245
- Springer Nature Limited
This article is cited by
-
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
Frontiers of Medicine (2018)
-
Correlation of TGF-β1 and oxidative stress in the blood of patients with melanoma: a clue to understanding melanoma progression?
Tumor Biology (2016)
-
TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma
Biological Research (2015)
-
Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine
Journal of Ovarian Research (2015)
-
Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells
Cancer Immunology, Immunotherapy (2015)